NCM · Biotechnology

CalciMedica, Inc. (CALC) Stock

$0.73 -3.82% NCM: CALC Healthcare

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.

Valuation

MetricValue
Price$0.73
Market Cap$11.55M
P/E Ratio-0.57
P/B Ratio-10.33
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$7.20
52-Week Low$0.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-7.61%
ROA-227.02%
ROCE-674.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-1.43
Current Ratio3.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-36.0M$-14.0M$-38.0M$-24.0M$-23.0M
Net Profit$-36.0M$-8.0M$-34.0M$-14.0M$-30.0M
EPS$-23.66$-23.20$-7.65$-1.22$-1.97
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$69.0M$3.0M$12.0M$20.0M$14.0M
Total Liabilities$4.0M$13.0M$4.0M$5.0M$20.0M
Cash$13.0M$1.0M$6.0M$8.0M$12.0M
Borrowings$0$5.0M$0$0$10.0M

Latest News

CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review MT Newswires · Jun 24, 2026 CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire · Jun 24, 2026 CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire · Jun 24, 2026 CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates PR Newswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-31.0M$-12.0M$-26.0M$-21.0M$-21.0M
Investing Cash Flow$10.0M$0$9.0M$-4.0M$10.0M
Financing Cash Flow$0$0$-5.0M$0$0
Net Cash Flow$-20.0M$-3.0M$4.0M$2.0M$4.0M
Free Cash Flow$-32.0M$-12.0M$-26.0M$-21.0M$-21.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.20
EV / EBITDA-0.16
FCF Yield-181.87%
Quick Ratio3.50
Interest Coverage-23.00
Return 1Y-61.88%
Return 3Y-78.76%
Return 5Y—

Ownership

Insiders Held26.50%
Institutions Held35.49%
Institutions Float Held48.29%
Institutional HolderSharesReport Date
Jane Street Group, LLC178,5152026-03-31
Vanguard Capital Management LLC169,1102026-03-31
Renaissance Technologies, LLC128,0752026-03-31
Geode Capital Management, LLC123,3822026-03-31
180 Wealth Advisors, LLC83,4002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%
LTRN $2.63 -0.75% -2.02 $33.56M 0.00%
LVTXLAVA Therapeutics N.V. $1.74 -3.87% -2.42 $45.77M 0.00%
MAIA $1.42 +0.00% -1.84 $86.34M 0.00%

About CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

CalciMedica, Inc. is led by CEO A. Rachel Leheny, employs 14 people, headquartered in US, publicly traded since 2023.

CalciMedica, Inc. (CALC) stock trades at $0.73 with a market capitalization of $11.55M. The stock is valued at a price-to-earnings (P/E) ratio of -0.57, price-to-book of -10.33, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.46 and $7.20, and currently trades 89.9% below its 52-week high.

On profitability, CalciMedica, Inc. generates a return on equity (ROE) of -7.61%, return on capital employed of -674.61%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.calcimedica.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides